GMED vs IOVA
Globus Medical vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | GMED | IOVA |
|---|
| AI Score |
71
|
67
|
| Price |
$85.12
|
$6.49
|
| P/E Ratio |
21.45×
|
-9.27×
|
| ROE |
11.8%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
116.3%
|
| Debt / Equity |
0.02×
|
0.06×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
79.2
|
| Beta |
0.954
|
0.701
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus IOVA.
GMED leads by 4 points.
GMED scores 71/100 (Buy) versus IOVA at 67/100 (Buy).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical